Hengrui Pharma (Hengrui) and Kailera Therapeutics, Inc. (Kailera) announced positive topline data from Hengrui's Phase 2 clinical trial of once-daily oral ribupatide (also known as HRS9531 tablet and KAI-9531-T), a GLP-1/GIP receptor dual agonist peptide, in 166 adults living with obesity in China (NCT06841445). Participants receiving oral ribupatide demonstrated a mean weight reduction from baseline of up to 12.1% at 26 weeks based on the efficacy estimandI with no observed plateau in weight loss, and vomiting reported in no more than 11.4% of participants taking oral ribupatide. These data highlight the potential to deliver a differentiated oral medication for the treatment of obesity in China.
The Hengrui Phase 2 clinical trial results mark an important milestone in the expansion of ribupatide franchise.
